This study is testing a new treatment called Senza5 CART5 for people with T Cell Non-Hodgkin Lymphoma (NHL) that has come back or not responded to previous treatments. Senza5 CART5 uses your own immune cells, called T cells, which are specially modified to fight the cancer. This is a Phase 1 study, meaning the main goal is to find the safest and most effective dose of Senza5 CART5. Researchers will also look at how well the treatment works. You may be able to join if you are 18 or older and have certain types of T-cell NHL that are CD5-positive. The study plans to enroll about 30 participants, but the current recruitment status is unclear.

Study design

This is an open-label Phase 1 study, meaning both you and your doctors will know which treatment you are receiving. It will involve up to 30 participants and test different dose levels of Senza5 CART5.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary goal of determining the recommended dose will be measured at 12 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.